Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Finally! Go spread the love dr!
Inovio Wins Deloitte’s “Fast 500” Growth Award
Developer of DNA-based Immunotherapies Recognized For its Ability to Attract Grants and Partnerships
PLYMOUTH MEETING, Pa. – November 16, 2016 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO), today announced it ranked No. 107 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2012 to 2015. During this period Inovio’s revenue growth reached 885.1%, based on revenue received from grants, partnerships and licensing deals.
Dr. J. Joseph Kim, Inovio's President and CEO, said, “We appreciate Deloitte’s recognition of Inovio’s growth based on our advancement of DNA immunotherapies and vaccines for cancers and infectious diseases. Our growth is fueled by the innovative spirit of our scientists, engineers and business people. At our company’s core; however, the Inovio team is motivated by our most important value: “Patients are waiting.”
“This year’s Fast 500 winners showcase that when organizations are open to diverse perspectives and insights, they are able to create an environment for their employees and investors to see the possibilities and ingenious solutions that might lie ahead,” added Jim Atwell, Deloitte’s national managing partner of the emerging growth practice. “Entrepreneurial environments foster change and innovation within businesses, and we look forward to watching these companies continue to drive change across all sectors.”
About Deloitte’s 2016 Technology Fast 500™
Deloitte’s Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2012 to 2015. Overall, 2016 Technology Fast 500™ companies achieved revenue growth ranging from 121 percent to 66,661 percent from 2012 to 2015, with median growth of 290 percent.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
# # # #
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, including the Zika vaccine GLS-5700, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended September 30, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Sent to:thomas.billiouw@telenet.be
If you prefer not to receive
future e-mails of this type,
click here
Sent By:
Inovio Pharmaceuticals
660 W. Germantown Pike
Plymouth Meeting Pennsylvania 19462
United States
To view as a web page click here.
Singing the same song every day is rather borring...
Nice tute accumulation ongoing! You were right.
Read the post to which i was replying...
Better inform DARPA, MedImmune,... that they are in with proven rubbish...
Did he mention sigma-1 or muscarinic?
Waiting for this PK/PD data for about a year know...
Why does it take this long ? Missling said publicly it would be released wants they have it.
Each to his own opinion.
7 patients.
They are not representative of any population. For all we know they are medical anomalies, like the few people how cure hiv/aids on there own.
Population size needs to be a lot bigger to be representative. That's why the FDA requires bigger patient sizes in phase 3.
As for Adam F. Keep the personal out please.
i will clarify for your purpose: "nothing significant".
The mono-data needs to be confirmed to be accepted as representative. Until then this could be an anomaly. Or it could be very meaningful. Who knows!
There are only 7 mono patients. Means nothing until confirmed in larger trial.
You forgot to mention either sigma-1 or muscarinic. Those are the keywords to trigger reaction.
No they will not act soon, they are a ship a drift with a captain that will thrown overboard without a replacement.
Yes they do need a winning drug sooner rather then later, e.g. 2-73
Our stock is on no one's radar. Profile awareness is why we have Bonfiglio on board. Watch upcoming investment conferences. And last but not least: trials are recruiting, so we await news.
It contains muscarinic and/or sigma-1. What do you want more?
Will we have the PK/PD data? Been waiting the whole year for those...
Only shareholders get a cookie from Punit!
Let's take 30% responders. So 40% of the non-responders makes a total of 30+28=58% total response rate.
Not bad, but expectations were higher in my mind (perhaps unrealistic my!)
Don't get me wrong, for the patients this is a good step forward to a cure.
Is it incredible?? To be honest I am disappointed. Was expecting higher.
Pr is out: 40% ORR
It helps when one reads the SEC forms. After the warrant reshuffle there are still warrants left at various time points and price points that can be used for raising funds. Those are baked in shares.
Filtering information is very important when doing due diligence.
Oh such enligthend statement! We are in the best cash position since a long time. Especially when others like the DOD pay for our trials.
I guess everybody is waiting till next Wednesday. Something huge happens on Tuesday and no it is not the uplisting ;)
Or perhaps dr MacFarlane goes blabbing again to the press. If anything needs to be gagged it's him!
Bring on those funds Michael, and the PR!
It's a phase 2a: primary endpoint is safety, secondary is efficacy
The only thing missing is money. Clock is ticking...
Big boys don't buy on OTC and we already have a 50% institutional ownership
I guess nothing in the next 84 years can be as big a scam as Anavex!
And all that whilst being a printing company ;)
For transparency, read the SEC fillings, listen to the most recent webcast
Are we taking the philosophical route today? ;)
Excellent news, and my add *finally* :)
Yeah, just ask DARPA or MedImmune
I fully agree that INO share price is cheap at the moment.
Yeah the Motley FOOL for investment advice... Such great scientific knowledge to judge a company.
Insiders are heavily invested ?
By my recollection all shares that Missling has, except a couple of thousand bought in June 2015, have all been granted to dr Missling. So no he has not really invested his money.